10x Genomics (TXG) Return on Invested Capital (2019 - 2020)
10x Genomics (TXG) reported Return on Invested Capital of 0.1% for Q3 2020, up 3.0% on a YoY basis from 0.1% in Q4 2019, and down 120.54% sequentially from 0.04% in Q2 2020.
10x Genomics (TXG) Return on Invested Capital (2019 - 2020) Analysis & Trends
10x Genomics (TXG) has 2 years of Return on Invested Capital data on file, last reported at 0.1% in Q3 2020.
- For the quarter ending Q3 2020, Return on Invested Capital rose 3.0% year-over-year to 0.1%; the trailing twelve-month figure through Sep 2020 stood at 0.1% (up 3.0% YoY), and the FY2019 full-year result was 0.04%, changed N/A from the prior year.
- Return on Invested Capital declined to 0.1% in Q3 2020, from 0.04% in the prior quarter.
- In the past five years, Return on Invested Capital ranged from a high of 0.02% in Q4 2019 to a low of 0.12% in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 29.34 Bn | 22.03 Bn | 662.02 Mn | - |
| 2 | BrightSpring Health Services | 13.49 Bn | 12.59 Bn | 482.22 Mn | 0.01% |
| 3 | Healthequity | 7.96 Bn | 7.70 Bn | 256.31 Mn | - |
| 4 | 10x Genomics | 6.17 Bn | 5.63 Bn | 106.18 Mn | - |
| 5 | Hinge Health | 6.02 Bn | 5.70 Bn | 154.23 Mn | - |
| 6 | MiniMed | 4.19 Bn | 3.89 Bn | 480.00 Mn | - |
| 7 | Waystar Holding | 4.14 Bn | 4.07 Bn | 216.84 Mn | 0.05% |
| 8 | Doximity | 3.82 Bn | 3.08 Bn | 125.97 Mn | - |
| 9 | Privia Health | 3.10 Bn | 2.73 Bn | - | - |
| 10 | Omnicell | 1.81 Bn | 1.57 Bn | 140.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -0.10% |
| Jun 30, 2020 | -0.04% |
| Mar 31, 2020 | -0.03% |
| Dec 31, 2019 | -0.02% |
| Sep 30, 2019 | -0.12% |